Ascletis Submits FDA Application for Innovative Oral Treatment of Obesity
Ascletis Takes a Bold Step in Obesity Treatment
Ascletis Pharma Inc., a prominent biotechnology firm, has recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). This application is for ASC36_37o FDC, a groundbreaking once-weekly oral fixed-dose combination tablet aimed at treating obesity. The medication combines four validated obesity-targeting peptide agonists: the amylin receptor, GLP-1R, GIPR, and GCGR.
The Significance of ASC36_37o FDC
Ascletis's newly proposed treatment stands out as potentially the first of its kind in the realm of oral obesity medications. According to Dr. Jinzi Jason Wu, the Founder, Chairman, and CEO of Ascletis, ASC36_37o FDC represents a milestone in obesity treatment by combining these four critical targets into one single digestible tablet. This innovation not only aims to simplify patient compliance by offering once-a-week dosing, but it also seeks to enhance the effectiveness through a synergistic approach.
Advanced Research and Development
The development of ASC36_37o FDC is rooted in Ascletis's proprietary technologies, including the Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD). These innovations have enabled the company to create two distinct peptide agonists, ASC36 and ASC37, both of which have shown promise in preclinical studies. Notably, the oral bioavailability for both peptides is impressive, exceeding 10% for ASC36 and reaching around 9.1% for ASC37.
In non-human primate studies, these treatments demonstrated incredibly extended half-lives, supporting a potential dosing schedule of once weekly. By combining these agonists, the co-formulation exhibited significant weight loss results; co-treatment with ASC36 and ASC37 yielded around 69% better weight reduction compared to using ASC37 alone. Furthermore, there's evidence suggesting a staggering 192% greater weight loss compared to ASC36 monotherapy. This data could signal a revolutionary shift in how obesity is approached pharmacologically.
Building on Previous Successes
This submission is a continuation of Ascletis's commitment to tackling obesity through innovative pharmaceutical solutions. The company is also advancing a portfolio of oral small molecules and peptides targeting related metabolic pathways, including a once-daily oral small molecule GLP-1R agonist, currently under evaluation in two global Phase III studies. The upcoming data from these studies is anticipated to add to the mounting body of evidence underscoring the potential impact of Ascletis's advancements in the field.
The Future of Obesity Treatment
With the growing prevalence of obesity and related metabolic disorders worldwide, the need for innovative therapeutic options has never been more pressing. Ascletis’s ASC36_37o FDC represents not just a new medication but a new paradigm in obesity management. It embodies a strategic shift towards developing comprehensive, multi-target approaches that enhance treatment efficacy while improving patient adherence.
As the company awaits feedback from the FDA regarding its IND application, the medical community watches closely. Should this treatment receive approval, it may significantly alter the landscape of obesity treatment, offering patients more effective tools to manage their condition.
Conclusion
Ascletis Pharma Inc. continues to lead the charge in biomedicine with innovative solutions to longstanding health challenges. The submission of the IND application for ASC36_37o FDC marks a hopeful chapter in the ongoing battle against obesity, potentially making strides towards a healthier future for those affected by this complex condition.